• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG
Click for more information
0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $5.671M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GTG 2014 Annual General Meeting materials25/11/14
GTG +Divestment of Australian heritage business completedPRICE SENSITIVE19/11/14
GTG Nasdaq Notice06/11/14
GTG Appendix 3B31/10/14
GTG US Annual Report on Form 20-F30/10/14
GTG Quarterly Reports - September 30 2014PRICE SENSITIVE28/10/14
GTG Notice of 2014 AGM, Sample Proxy and Annual Report27/10/14
GTG Appendix 3B20/10/14
GTG BREVAGen test numbers - September quarter 2014PRICE SENSITIVE06/10/14
GTG Appendix 3B02/10/14
GTG New Generation Test - BREVAGenplus LaunchPRICE SENSITIVE01/10/14
GTG Results from 2014 EGM30/09/14
GTG Financial Report - 30 June 201430/09/14
GTG Appointment of Non-Executive Directors24/09/14
GTG Divestment of Australian heritage business22/09/14
GTG Reinstatement to Official QuotationPRICE SENSITIVE15/09/14
GTG Financing and Restructure Plan FinalisedPRICE SENSITIVE15/09/14
GTG Suspension from Official QuotationPRICE SENSITIVE11/09/14
GTG Trading HaltPRICE SENSITIVE09/09/14
GTG Nasdaq deficiency notice03/09/14
GTG ASX Appendix 4E - 30 June 2014PRICE SENSITIVE29/08/14
GTG Notice of EGM and sample form of proxy28/08/14
GTG Further Patent Success in USAPRICE SENSITIVE26/08/14
GTG Appendix 3B20/08/14
GTG Settlement with Histogenetics LLC14/08/14
GTG Appendix 3B12/08/14
GTG Appendix 3B31/07/14
GTG Quarterly Reports - 30 June 2014PRICE SENSITIVE31/07/14
GTG Appendix 3B09/07/14
GTG Return to growth in BREVAGen test numbersPRICE SENSITIVE04/07/14
GTG Appendix 3B27/06/14
GTGAppendix 3B03/06/14
GTGAppointment of Chief Financial Officer29/05/14
GTGASIC Form 48428/05/14
GTGChange in substantial holding23/05/14
GTGCompletion of share transactions with Dr. Mervyn JacobsonPRICE SENSITIVE16/05/14
GTGQuarterly Reports - 31 March 2014PRICE SENSITIVE30/04/14
GTGResults from Extraordinary General Meeting17/04/14
GTGAppendix 3B10/04/14
GTGSettlement with Promega CorporationPRICE SENSITIVE24/03/14
GTGASX Appendix 3B20/03/14
GTGNotice of EGM and sample Form of Proxy13/03/14
GTGFurther patent success in USAPRICE SENSITIVE12/03/14
GTGEconomic modelling supports cost-effectiveness of BREVAGenPRICE SENSITIVE07/03/14
GTGFurther update on corporate structure24/02/14
GTGASX Appendix 4D with Financial ReportPRICE SENSITIVE20/02/14
GTGAppendix 3B18/02/14
GTGAppendix 3B12/02/14
GTGPatent re-examination certificate issuedPRICE SENSITIVE12/02/14
GTGQuarterly Reports - 31 December 2013PRICE SENSITIVE30/01/14
GTGAppendix 3B20/01/14
GTGUS investor presentation08/01/14
GTGGTG announces continued growth in number of BREVAGen testsPRICE SENSITIVE08/01/14
GTGUpdate on corporate structure07/01/14
GTGSettlement with ReprogeneticsPRICE SENSITIVE07/01/14
GTGASX Appendix 3B02/01/14
GTGLicensing update - December 2013PRICE SENSITIVE24/12/13
GTGIssue of convertible note and receipt of funds23/12/13
GTGNotice of change of interests of substantial holder19/12/13
GTGConvertible note and cleansing notice19/12/13
GTGShare transactions with major shareholderPRICE SENSITIVE18/12/13
GTGTrading HaltPRICE SENSITIVE18/12/13
GTGAppointment of Dr. Paul Kasian12/12/13
GTGGtech International completes acquisition of Simavita12/12/13
GTGPublication of BREVAGen cost effectiveness study06/12/13
GTGASX Appendices 3X and 3Z04/12/13
GTGResults of EGM and AGM and appointment of Directors29/11/13
GTG2013 Annual General Meeting materials29/11/13
GTGWithdrawal of nomination - Ben Silluzio28/11/13
GTGASX Appendix 3B18/11/13
GTGWithdrawal of nomination - Tom Bonvino14/11/13
GTGQuarterly Activites Report and ASX Appendix 4CPRICE SENSITIVE31/10/13
GTGUS Annual Report on Form 20-F31/10/13
GTGNotice of 2013 AGM, Sample Proxy, Letter and Annual Report25/10/13
GTGResults from 2013 Extraordinary General Meeting23/10/13
GTGTemporary corporate restructurePRICE SENSITIVE15/10/13
GTGCleansing notice and ASX Appendix 3B08/10/13
GTGResults of share purchase planPRICE SENSITIVE03/10/13
GTGGTG announces further record number of BREVAGen testsPRICE SENSITIVE01/10/13
GTGTermination of patent re-examinationPRICE SENSITIVE30/09/13
GTGFinancial Report - 30 June 201327/09/13
GTGImmunAid fundraising update26/09/13
GTGNotice of EGM and sample form of proxy19/09/13
GTGSettlement with Genelex Corporation17/09/13
GTGAppendix 3B - granting of options11/09/13
GTGExecution of convertible note documents10/09/13
GTGSettlement with Genesis GeneticsPRICE SENSITIVE03/09/13
GTGCleansing notice and ASX Appendix 3B30/08/13
GTGASX Appendix 4E - 30 June 2013PRICE SENSITIVE30/08/13
GTGGTG receives certification for New York StatePRICE SENSITIVE30/08/13
GTGFund raising updatePRICE SENSITIVE27/08/13
GTGExecution of eighth PPO agreementPRICE SENSITIVE22/08/13
GTGShare Purchase Plan documents20/08/13
GTGCleansing notice and ASX Appendix 3B14/08/13
GTGFund raising updatePRICE SENSITIVE01/08/13
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/13
GTGTrading HaltPRICE SENSITIVE30/07/13
GTGGtech International executes Merger AgreementPRICE SENSITIVE30/07/13
GTGUS Patent Office allows first US patent to ImmunAidPRICE SENSITIVE10/07/13
GTGGTG announces record number of BREVAGen tests01/07/13
GTG 2014 Annual General Meeting materials
25/11/14
GTG +Divestment of Australian heritage business completed
19/11/14PRICE SENSITIVE
GTG Nasdaq Notice
06/11/14
GTG Appendix 3B
31/10/14
GTG US Annual Report on Form 20-F
30/10/14
GTG Quarterly Reports - September 30 2014
28/10/14PRICE SENSITIVE
GTG Notice of 2014 AGM, Sample Proxy and Annual Report
27/10/14
GTG Appendix 3B
20/10/14
GTG BREVAGen test numbers - September quarter 2014
06/10/14PRICE SENSITIVE
GTG Appendix 3B
02/10/14
GTG New Generation Test - BREVAGenplus Launch
01/10/14PRICE SENSITIVE
GTG Results from 2014 EGM
30/09/14
GTG Financial Report - 30 June 2014
30/09/14
GTG Appointment of Non-Executive Directors
24/09/14
GTG Divestment of Australian heritage business
22/09/14
GTG Reinstatement to Official Quotation
15/09/14PRICE SENSITIVE
GTG Financing and Restructure Plan Finalised
15/09/14PRICE SENSITIVE
GTG Suspension from Official Quotation
11/09/14PRICE SENSITIVE
GTG Trading Halt
09/09/14PRICE SENSITIVE
GTG Nasdaq deficiency notice
03/09/14
GTG ASX Appendix 4E - 30 June 2014
29/08/14PRICE SENSITIVE
GTG Notice of EGM and sample form of proxy
28/08/14
GTG Further Patent Success in USA
26/08/14PRICE SENSITIVE
GTG Appendix 3B
20/08/14
GTG Settlement with Histogenetics LLC
14/08/14
GTG Appendix 3B
12/08/14
GTG Appendix 3B
31/07/14
GTG Quarterly Reports - 30 June 2014
31/07/14PRICE SENSITIVE
GTG Appendix 3B
09/07/14
GTG Return to growth in BREVAGen test numbers
04/07/14PRICE SENSITIVE
GTG Appendix 3B
27/06/14
GTGAppendix 3B
03/06/14
GTGAppointment of Chief Financial Officer
29/05/14
GTGASIC Form 484
28/05/14
GTGChange in substantial holding
23/05/14
GTGCompletion of share transactions with Dr. Mervyn Jacobson
16/05/14PRICE SENSITIVE
GTGQuarterly Reports - 31 March 2014
30/04/14PRICE SENSITIVE
GTGResults from Extraordinary General Meeting
17/04/14
GTGAppendix 3B
10/04/14
GTGSettlement with Promega Corporation
24/03/14PRICE SENSITIVE
GTGASX Appendix 3B
20/03/14
GTGNotice of EGM and sample Form of Proxy
13/03/14
GTGFurther patent success in USA
12/03/14PRICE SENSITIVE
GTGEconomic modelling supports cost-effectiveness of BREVAGen
07/03/14PRICE SENSITIVE
GTGFurther update on corporate structure
24/02/14
GTGASX Appendix 4D with Financial Report
20/02/14PRICE SENSITIVE
GTGAppendix 3B
18/02/14
GTGAppendix 3B
12/02/14
GTGPatent re-examination certificate issued
12/02/14PRICE SENSITIVE
GTGQuarterly Reports - 31 December 2013
30/01/14PRICE SENSITIVE
GTGAppendix 3B
20/01/14
GTGUS investor presentation
08/01/14
GTGGTG announces continued growth in number of BREVAGen tests
08/01/14PRICE SENSITIVE
GTGUpdate on corporate structure
07/01/14
GTGSettlement with Reprogenetics
07/01/14PRICE SENSITIVE
GTGASX Appendix 3B
02/01/14
GTGLicensing update - December 2013
24/12/13PRICE SENSITIVE
GTGIssue of convertible note and receipt of funds
23/12/13
GTGNotice of change of interests of substantial holder
19/12/13
GTGConvertible note and cleansing notice
19/12/13
GTGShare transactions with major shareholder
18/12/13PRICE SENSITIVE
GTGTrading Halt
18/12/13PRICE SENSITIVE
GTGAppointment of Dr. Paul Kasian
12/12/13
GTGGtech International completes acquisition of Simavita
12/12/13
GTGPublication of BREVAGen cost effectiveness study
06/12/13
GTGASX Appendices 3X and 3Z
04/12/13
GTGResults of EGM and AGM and appointment of Directors
29/11/13
GTG2013 Annual General Meeting materials
29/11/13
GTGWithdrawal of nomination - Ben Silluzio
28/11/13
GTGASX Appendix 3B
18/11/13
GTGWithdrawal of nomination - Tom Bonvino
14/11/13
GTGQuarterly Activites Report and ASX Appendix 4C
31/10/13PRICE SENSITIVE
GTGUS Annual Report on Form 20-F
31/10/13
GTGNotice of 2013 AGM, Sample Proxy, Letter and Annual Report
25/10/13
GTGResults from 2013 Extraordinary General Meeting
23/10/13
GTGTemporary corporate restructure
15/10/13PRICE SENSITIVE
GTGCleansing notice and ASX Appendix 3B
08/10/13
GTGResults of share purchase plan
03/10/13PRICE SENSITIVE
GTGGTG announces further record number of BREVAGen tests
01/10/13PRICE SENSITIVE
GTGTermination of patent re-examination
30/09/13PRICE SENSITIVE
GTGFinancial Report - 30 June 2013
27/09/13
GTGImmunAid fundraising update
26/09/13
GTGNotice of EGM and sample form of proxy
19/09/13
GTGSettlement with Genelex Corporation
17/09/13
GTGAppendix 3B - granting of options
11/09/13
GTGExecution of convertible note documents
10/09/13
GTGSettlement with Genesis Genetics
03/09/13PRICE SENSITIVE
GTGCleansing notice and ASX Appendix 3B
30/08/13
GTGASX Appendix 4E - 30 June 2013
30/08/13PRICE SENSITIVE
GTGGTG receives certification for New York State
30/08/13PRICE SENSITIVE
GTGFund raising update
27/08/13PRICE SENSITIVE
GTGExecution of eighth PPO agreement
22/08/13PRICE SENSITIVE
GTGShare Purchase Plan documents
20/08/13
GTGCleansing notice and ASX Appendix 3B
14/08/13
GTGFund raising update
01/08/13PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/13PRICE SENSITIVE
GTGTrading Halt
30/07/13PRICE SENSITIVE
GTGGtech International executes Merger Agreement
30/07/13PRICE SENSITIVE
GTGUS Patent Office allows first US patent to ImmunAid
10/07/13PRICE SENSITIVE
GTGGTG announces record number of BREVAGen tests
01/07/13
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
US election outcomes: Key economic and market takeaways This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.